Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses (2016 - 2025)
Arrowhead Pharmaceuticals (ARWR) has disclosed Accumulated Expenses for 16 consecutive years, with $26.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accumulated Expenses rose 22.31% year-over-year to $26.9 million, compared with a TTM value of $26.9 million through Sep 2025, up 22.31%, and an annual FY2025 reading of $26.9 million, up 22.31% over the prior year.
- Accumulated Expenses was $26.9 million for Q3 2025 at Arrowhead Pharmaceuticals, down from $64.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $64.8 million in Q2 2025 and bottomed at $2.9 million in Q1 2021.
- Average Accumulated Expenses over 5 years is $24.3 million, with a median of $18.5 million recorded in 2021.
- Peak annual rise in Accumulated Expenses hit 950.49% in 2023, while the deepest fall reached 86.36% in 2023.
- Year by year, Accumulated Expenses stood at $18.5 million in 2021, then soared by 160.15% to $48.2 million in 2022, then plummeted by 81.78% to $8.8 million in 2023, then soared by 150.53% to $22.0 million in 2024, then grew by 22.31% to $26.9 million in 2025.
- Business Quant data shows Accumulated Expenses for ARWR at $26.9 million in Q3 2025, $64.8 million in Q2 2025, and $16.6 million in Q1 2025.